# Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

> **NCT00103194** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 49 (actual)

## Conditions studied

- Recurrent Prostate Cancer
- Stage I Prostate Cancer
- Stage IIA Prostate Cancer
- Stage IIB Prostate Cancer
- Stage III Prostate Cancer

## Interventions

- **DRUG:** lapatinib ditosylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00103194
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2014-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00103194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00103194, "Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00103194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*